Mitogen-Activated Protein Kinase Pathway: Genetic Analysis of 95 Adrenocortical Tumors

Beatrice RubinDivision of Endocrinology, Department of Medicine (DIMED), University of Padua, Padua, ItalyCorrespondence[email protected]

Halenya MonticelliDivision of Endocrinology, Department of Medicine (DIMED), University of Padua, Padua, Italy

Marco RedaelliDepartment of Molecular Medicine, University of Padua, Padua, Italy

Carla MucignatDepartment of Molecular Medicine, University of Padua, Padua, Italy

Susi BarolloDivision of Endocrinology, Department of Medicine (DIMED), University of Padua, Padua, Italy

Loris BertazzaDivision of Endocrinology, Department of Medicine (DIMED), University of Padua, Padua, Italy

Caterina MianDivision of Endocrinology, Department of Medicine (DIMED), University of Padua, Padua, Italy

Corrado BetterleDivision of Endocrinology, Department of Medicine (DIMED), University of Padua, Padua, Italy

Maurizio IacoboneDivision of Minimally Invasive Endocrine Surgery, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy

Ambrogio FassinaDivision of Pathology and Cytopathology, Department of Medicine (DIMED), University of Padua, Padua, Italy

Marco BoscaroDivision of Endocrinology, Department of Medicine (DIMED), University of Padua, Padua, Italy

Raffaele PezzaniDivision of Endocrinology, Department of Medicine (DIMED), University of Padua, Padua, Italy

Franco ManteroDivision of Endocrinology, Department of Medicine (DIMED), University of Padua, Padua, Italy

show all

Abstract

Mitogen-activated protein kinase (MAPK) pathway is often deregulated in adrenocortical tumors (ACT) but with no concrete data confirming alteration rate. The objective of this study was to evaluate genetic alterations in key components of MAPK pathway. We found one BRAF mutation (p.V600E) and four HRAS silent mutations. No alteration was found in NRAS, KRAS, EGFR genes. The patient carrying BRAF mutation was further characterized by investigating his biomolecular and clinico-pathological findings. Therefore, even if MAPK signaling is activated in ACT, our results suggest that genetic alterations do not seem to represent a frequent mechanism of ACT tumorigenesis.

Keywords::

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Mitogen-Activated Protein Kinase Pathway: Genetic Analysis of 95 Adrenocortical Tumors

Information for

Open access

Opportunities

Help and information

Mitogen-Activated Protein Kinase Pathway: Genetic Analysis of 95 Adrenocortical Tumors

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature